While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

Eli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Estimates for Eli Lilly’s 2025 earnings have declined from $23.06 to $21.95 per share in the past 60 days, and estimates for 2026 earnings have declined from $31.15 to $30.91 over the same ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. ... This Phase II study, published in September 2023, ...

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...